Table of Contents U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) Delaware 75-3254381 (State or other jurisdiction of (I.R.S. employer incorporation or organization) identification number) 999 Skyway Road, Suite 150, San Carlos, CA 94070 (Address of principal executive offices and zip code) (650) 260-7120 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE ...

ASCO Update Call June 6, 2021 © 2021, Iovance Biotherapeutics, Inc 1 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------|-------------------------| | Agenda | | | | | | • Corporate Update : Fred Vogt, incoming Interim CEO and President • ASCO Updates for Lifileucel in Advanced Melanoma | : Omid Hamid, MD, Chief | | of Research/Immuno-Oncology, The Angeles Clinic & Research Institute | | | • Financial Summary : Jean-Marc B ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Maria Fardis - Chief Executive Officer & President Friedrich Finckenstein - Chief Medical Officer Jean Marc Bellemin - Chief Financial Officer Sara Pellegrino - Vice President, Investor and Public Relations Jim Ziegler - Senior Vice President, Commercial Conference Call Participants Michael Yee - Jefferies LLC Peter Lawson - Barclays Bank Mark Breidenbach - Oppenheimer Boris Peaker - Cowe ...

Table of Contents U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) Delaware 75-3254381 (State or other jurisdict ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | --- | --- ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | --- | --- ...

| --- | --- | --- | --- | --- | |---------------------------------------------------------------------------|--------------------------------------|-------|---------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors | | | February 2021 | | | | © 2021, Iovance Biotherapeutics, Inc | | | 1 | | --- ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Maria Fardis - Chief Executive Officer & President Friedrich Finckenstein - Chief Medical Officer Jean Marc Bellemin - Chief Financial Officer Sara Pellegrino - Vice President, Investor and Public Relations Conference Call Participants Mark Breidenbach - Oppenheimer Peter Lawson - Barclays Bank Biren Amin - Jefferies Reni Benjamin - JMP Securities Mara Goldstein - Mizuho Securities ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from __________ to __________ Commission file number: 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Del ...

| --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|---------------------------------|-------|---------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer | | | November 2020 | | | | © 2020, Iovance Biotherapeutics | | | | ongoing clinical trials and anticipated clinical trials for our current product candidates (including both Company ...